Key facts
- This page summarizes BIOGEN INC.'s Form 3 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Apr 2026, 18:11.
BIOGEN INC. - 31 Mar 2026 Form 3 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Other*
- Issuer ticker
- APLS
- Reported as of
- 31 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Apr 2026, 18:11:26 UTC
- Prior SEC filing
- 28 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wendell Taylor, Secretary, Biogen Inc.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
BIOGEN INC. filed Form 3 for Apellis Pharmaceuticals, Inc. (APLS) on 06 Apr 2026.
Change
- Previous filing in this sequence was filed on 28 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0000875045
Primary reporting owner
BIOGEN INC.
- Relationship
- Other*
- Address
- 225 BINNEY STREET, CAMBRIDGE
- Signature
- /s/ Wendell Taylor, Secretary, Biogen Inc.
- Signature date
- 06 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
APLS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 31 Mar 2026
- Ownership
- See footnotes
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
holding
Derivative
Stock Options
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 Mar 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 0
- Exercise price
- $0.000000
- Footnotes
- F1, F2, F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The reporting person entered into a Tender and Support Agreement, dated March 31, 2026 (the "Tender and Support Agreement") with respect to the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Apellis Pharmaceuticals, Inc. (the "Issuer") held by each of (i) Morningside Venture Investments, Ltd., (ii) Cedric Francois, (iii) Gerald Chan, (iv) Alec Machiels, and (v) Pascal Deschatelets (each, a "Holder" and, collectively, the "Holders").
Footnote F2
By virtue of entering into the Tender and Support Agreement, dated March 31, 2026, with each of the Holders, the reporting person on this Form 3 may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities and Exchange Act of 1934, as amended (the "Exchange Act") with respect to the securities held by parties who continue to be bound by the Tender and Support Agreement, which such "group" beneficially owns (as defined in Section 13(d) of the Exchange Act), in the aggregate, more than 10% of the outstanding Common Stock. Pursuant to the Tender and Support Agreement, the Holders agreed to irrevocably and unconditionally appoint the reporting person, or any person designated by the reporting person, as its proxy and attorney-in-fact to vote such Holders' Common Stock for certain matters as set forth in the Tender and Support Agreement.
Footnote F3
The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.
Footnote F4
Each of Messrs Chan, Deschatelets, Francois and Machiels holds Restricted Stock Units ("RSUs") in the amount and on the terms reported on each of Messrs Chan, Deschatelets, Francois and Machiels' past and current Form 3 and Form 4 filings with respect to the Issuer, as amended. The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock underlying such RSUs and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.
Footnote F5
Each of Messrs Chan, Deschatelets, Francois and Machiels holds options for Common Stock (the "Options"), which are currently outstanding and unexercised as of March 31, 2026, in the amount and on the terms reported on each of Messrs Chan, Deschatelets, Francois and Machiels' past and current Form 3 and Form 4 filings with respect to the Issuer, as amended. The Tender and Support Agreement does not provide the reporting person with a pecuniary interest in the Common Stock underlying such Options and as such the reporting person is not a beneficial owner for purposes of Section 16 of the Exchange Act.